Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Patrick Wilson

Senior Respiratory Pharmacist, Glenfield Hospital, Leicester

Recent stories

  • Generic prescribing is not appropriate for inhaled drugsSubscription

    8 JAN 2015Comments (3)

    The UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clinical practice is important because they may vary in type of inhaler device and licensing. One product is DuoRespSpiromax, a cheaper “branded generic” of Symbicort Turbohaler, both containing

  • Primum non nocereSubscription

    PJ, 7 June 2014, Vol 292, No 7813

    We welcome the comments from Stuart Hill providing a counter-argument to the concerns initially raised by the UK Clinical Pharmacy Association Respiratory Group about Relvar Ellipta.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.